You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆指午後升幅擴至逾500點 重上16,000關
官媒引述專家指不排除2月下調LPR及3月下調政策利率,港股恆指今早(6日)高開31點後升幅擴大,午後曾升535點或3.4%,一度重越萬六關,高見16,045;現報16,026,升516點或3.3%,成交712.83億元。國指及恆生科指午後升幅亦擴至4%及5.5%,報5,426及3,207。 權重金融股造好,友邦(01299.HK)漲3%、招行(03968.HK)、港交所(00388.HK)、國壽(02628.HK)、中國平安(02318.HK)漲4.9%至5.6%。匯控(00005.HK)及中銀香港(02388.HK)亦升0.9%至1.3%;另建行(00939.HK)、工行(01398.HK)及中行(03988.HK)亦升1.9%至2.4%。 藍籌內地及物管股升幅顯著,中海外(00688.HK)漲3.9%、龍湖(00960.HK)、潤地(01109.HK)及碧服(06098.HK)升5%至8.3%、萬象生活(01209.HK)亦升1.8%。 權重科技股集體上漲、網易-S(09999.HK)、騰訊(00700.HK)、美團-W(03690.HK)、京東-SW(09618.HK)、百度-SW(09888.HK)、小米-W(01810.HK)、攜程-S(09961.HK)升近3%至6%。即將公布季績的阿里-SW(09988.HK)急反彈6.9%,報75.5元。 早前急挫的藥明系兩藍籌造好,藥明生物(02269.HK)及藥明康德(02359.HK)漲5%至近8%。其他藍籌藥企/線上醫療股亦步亦趨,石藥(01093.HK)、中生製藥(01177.HK)、翰森(03692.HK)、國藥控股(01099.HK)、阿里健康(00241.HK)及京東健康(06618.HK)升4%至8.6%。 內需股受支持,李寧(02331.HK)、安踏(02020.HK)、蒙牛(02319.HK)及海底撈(06862.HK)各升3%至7%。汽車股走高,比亞迪(01211.HK)、吉利(00175.HK)及理想-W(02015.HK)漲5%至7.7%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account